摘要
心血管系统并发症是2型糖尿病患者最严重的并发症以及致死和致残的主要原因,其治疗核心是在有效降糖的同时对其他各种心血管疾病危险因素进行干预,以降低心血管疾病相关的死亡风险,改善患者预后。新型口服降糖药钠-葡萄糖协同转运蛋白-2抑制剂不仅可有效降糖,还可显著降低心血管疾病风险,同时具有良好的安全性,为糖尿病合并心血管疾病患者的管理提供了理想选择。现就钠-葡萄糖协同转运蛋白-2抑制剂在心血管获益的临床进展及指南推荐做一综述。
Cardiovascular complications are the most serious complication and the main cause of death and disability in patients with type 2 diabetes.The focus of treatment is reducing blood glucose effectively,while intervening various risk factors of cardiovascular diseases,to reduce the risk of death related to cardiovascular diseases and improve the prognosis of patients.The new oral hypoglycemic drug SGLT-2 inhibitor can not only reduce glucose effectively,but also significantly reduce the risk of cardiovascular diseases.At the same time,it has good safety and provides an ideal choice for the management of patients with cardiovascular diseases.This article reviews the clinical progress and guideline recommendations of SGLT-2 inhibitors in cardiovascular benefits.
作者
张国瑞
马赛
和丽丽
郭艺芳
ZHANG Guorui;MA Sai;HE Lili;GUO Yifang(Cardiology Department,The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University,Shijiazhuang 050011,Hebei,China;Geriatric Cardiology Department,Hebei General Hospital,Shijiazhuang 050051,Hebei,China)
出处
《心血管病学进展》
CAS
2021年第3期252-255,265,共5页
Advances in Cardiovascular Diseases
